The Beginning of the Trend Change in Lung Cancer Mortality Trends in Spain, 1980–2018

Cayuela, L.; Lόpez-Campos, José Luís; Otero, Remedios; Portal, José Antonio Rodríguez; Rodríguez-Domínguez, Susana; Cayuela, Aurelio

doi:10.1016/j.arbres.2020.04.025

Cited by 21 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The International Agency for Research on Cancer (ARC) estimated more than 2 million new cases of LC by 2020, 47 and some countries have changed the trend in the LC mortality. 48 However, these estimates are made without including the effects of the pandemic, so the number of diagnosed cases is likely to be lower. 49 …”

Section: Lung Cancermentioning

confidence: 99%

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases

Chiner-Vives

Cordovilla-Pérez

Rosa-Carrillo

et al. 2022

Archivos de Bronconeumología

View full text Add to dashboard Cite

Section: Lung Cancermentioning

confidence: 99%

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases

Chiner-Vives

Cordovilla-Pérez

Rosa-Carrillo

et al. 2022

Archivos de Bronconeumología

View full text Add to dashboard Cite

“…Lung cancer (LC) is a leading cause of death worldwide [1][2][3][4]. Surgical resection of lung tumors continues to be the main elective treatment in LC patients [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD

Tang

Curull

Wang

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background: Lung cancer (LC) is a major leading cause of death worldwide. Poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 are key players in cancer. We aimed to assess PARP-1 and PARP-2 expression and activity and DNA damage in tumors and non-tumor lungs from patients with/without chronic obstructive pulmonary disease (COPD). (2) Methods: Lung tumor and non-tumor specimens were obtained through video-assisted thoracoscopic surgery (VATS) in LC patients with/without underlying COPD (two groups of patients, n = 15/group). PARP-1 and PARP-2 expression (ELISA), PARP activity (PARP colorimetric assay kit) and DNA damage (immunohistochemistry) levels were identified in all samples. (3) Results: Both PARP-1 and PARP-2 expression levels were significantly lower in lung tumors (irrespective of COPD)compared to non-tumor specimens, while DNA damage and PARP activity levels significantly increased in lung tumors compared to non-tumor specimens only in LC-COPD patients. PARP-2 expression was positively correlated with smoking burden in LC-COPD patients. (4) Conclusions: In lung tumors of COPD patients, an overactivation of PARP enzyme was observed. A decline in PARP-1 and PARP-2 protein expression was seen in lung tumors irrespective of COPD. Other phenotypic features (airway obstruction) beyond cancer may account for the increase in PARP activity seen in the tumors of patients with underlying COPD.

show abstract

“…Despite these advances, the mortality rate continues to increase in women due to the progressive increase in the incidence of the disease. In Spain, lung cancer mortality rates have shown a downward trend in men and an upward trend in women since the early 1990s [ 50 ]. These patterns are similar to those observed in other European countries [ 51 , 52 ].…”

Section: Discussionmentioning

confidence: 99%

“…These patterns are similar to those observed in other European countries [ 51 , 52 ]. Although in Spain mortality in men is still much higher than in women, the proportion between sexes has drastically declined in the past three decades, from 13.3 in 1989 to 3.7 in 2018 [ 50 ]. In Europe, the corresponding proportion decreased from 5.1 in 1994 to 2.2 in 2019 [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

et al. 2022

View full text Add to dashboard Cite

Background Lung cancer is the third most frequent tumor and the main cause of death by tumor in Spain. Although the incidence and mortality are still significantly higher in men than in women, the disparity between the sexes is decreasing. The objective of this study was to analyze the evolution of lung cancer hospitalization and in-hospital mortality rates in Spain from 2010 to 2020. Methods The reports of the Minimum Basic Data Set (MBDS) at hospital discharge were used to retrospectively analyze the data of all patients with a primary diagnosis of lung cancer, according to the International Classification of Diseases (ICD-9-CM and ICD-10-CM). Results Between 2010 and 2020, there were 315,263 hospitalizations and 70,490 deaths from lung cancer in Spain, the majority (~ 80%) in men. Overall, the rates of hospitalization and in-hospital mortality from lung cancer showed a downward trend throughout the period, although the number of new diagnoses and the absolute number of deaths in women increased. Due to the aging of the population, the degree of comorbidity in patients with lung cancer, although it remains relatively low, is also on the rise. Conclusion Lung cancer represents a substantial clinical and economic burden for patients and for the National Health System, so it is necessary to promote primary prevention campaigns, as well as to develop more effective population screening measures to detect cancers early and increase the patient survival.

show abstract

The Beginning of the Trend Change in Lung Cancer Mortality Trends in Spain, 1980–2018

Cited by 21 publications

References 32 publications

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases

Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

Contact Info

Product

Resources

About